English
Regional settings| Spread | 0.11 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 10.43 |
| Open | 10.27 |
| 1-Year Change | -65.94% |
| Day's Range | 10.27 - 10.82 |
Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical irreversible programs for the treatment of select cancers.
BRIEF: For the fiscal year ended 31 December 2021, Biomea Fusion Inc revenues was not reported. Net loss increased from $5.3M to $41.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.19 to -$1.74.
